Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Salix Pharmaceuticals and Pharming Group NV announces FDA approval of RUCONEST for treatment of acute angioedema attacks in patients with Hereditary Angioedema


Thursday, 17 Jul 2014 01:00am EDT 

Salix Pharmaceuticals Ltd and Pharming Group NV:Says that the Food and Drug Administration has approved RUCONEST (C1 Esterase Inhibitor) 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema.Says because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAE patients with laryngeal attacks. 

Company Quote

159.83
-4.4 -2.68%
22 Sep 2014